These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17267332)

  • 1. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
    Frangié C; Lefaucheur C; Medioni J; Jacquot C; Hill GS; Nochy D
    Lancet Oncol; 2007 Feb; 8(2):177-8. PubMed ID: 17267332
    [No Abstract]   [Full Text] [Related]  

  • 2. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma.
    Roncone D; Satoskar A; Nadasdy T; Monk JP; Rovin BH
    Nat Clin Pract Nephrol; 2007 May; 3(5):287-93. PubMed ID: 17457362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic therapy in the treatment of advanced renal cell cancer.
    Board RE; Thistlethwaite FC; Hawkins RE
    Cancer Treat Rev; 2007 Feb; 33(1):1-8. PubMed ID: 17071006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer.
    Schrader AJ; Varga Z; Pfoertner S; Goelden U; Buer J; Hofmann R
    BJU Int; 2006 Mar; 97(3):461-5. PubMed ID: 16469008
    [No Abstract]   [Full Text] [Related]  

  • 5. From theoretical synergy to clinical supra-additive toxicity.
    Soria JC; Massard C; Izzedine H
    J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute renal failure in a patient receiving anti-VEGF therapy for advanced non-small cell lung cancer.
    Zhao J; Li H; Wang M
    J Thorac Oncol; 2009 Sep; 4(9):1185-7. PubMed ID: 19704343
    [No Abstract]   [Full Text] [Related]  

  • 7. Bevacizumab-induced hypertension: pathogenesis and management.
    Syrigos KN; Karapanagiotou E; Boura P; Manegold C; Harrington K
    BioDrugs; 2011 Jun; 25(3):159-69. PubMed ID: 21627340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
    Albiges L; Salem M; Rini B; Escudier B
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.
    Schmidinger M; Bellmunt J
    Cancer Treat Rev; 2010 Aug; 36(5):416-24. PubMed ID: 20163917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.
    Wilkes GM
    Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):54-6. PubMed ID: 19856612
    [No Abstract]   [Full Text] [Related]  

  • 12. VEGF inhibition and renal thrombotic microangiopathy.
    Eremina V; Jefferson JA; Kowalewska J; Hochster H; Haas M; Weisstuch J; Richardson C; Kopp JB; Kabir MG; Backx PH; Gerber HP; Ferrara N; Barisoni L; Alpers CE; Quaggin SE
    N Engl J Med; 2008 Mar; 358(11):1129-36. PubMed ID: 18337603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma.
    Harshman LC; Kuo CJ; Wong BY; Vogelzang NJ; Srinivas S
    Cancer Invest; 2009 Oct; 27(8):851-6. PubMed ID: 19603304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
    Harshman LC; Barbeau S; McMillian A; Srinivas S
    Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
    Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N
    Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines.
    Grepin R; Guyot M; Jacquin M; Durivault J; Chamorey E; Sudaka A; Serdjebi C; Lacarelle B; Scoazec JY; Negrier S; Simonnet H; Pages G
    Oncogene; 2012 Mar; 31(13):1683-94. PubMed ID: 21909141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Are antiangiogenic antibodies universal for solid tumor?].
    Ray-Coquard I; Bachelot T; Saba C; Confavreux C; Brantus JF; Rustam F; Ghesquière H; Sebban C; Biron P; Guastalla JP; Blay JY
    Bull Cancer; 2007 Jul; 94 Spec No():S191-6. PubMed ID: 17846004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.
    Powles T
    Clin Genitourin Cancer; 2012 Jun; 10(2):67-8. PubMed ID: 22608779
    [No Abstract]   [Full Text] [Related]  

  • 20. Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
    McDermott DF; George DJ
    Cancer Treat Rev; 2010 May; 36(3):216-23. PubMed ID: 20116176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.